Table 1 Patient characteristics
N = 49 (%) | |
|---|---|
Age (median(range)) | 68 (35–82) |
Gender | |
Female | 7 (14%) |
Male | 42 (86%) |
Disease | |
Locally advanced | 13 (27%) |
Metastatic | 36 (73%) |
Treatment | |
Cisplatin-gemcitabine | 24 (49%) |
Carboplatin-gemcitabine | 3 (6%) |
Pembrolizumab | 20 (41%) |
Vinflunine | 2 (4%) |
Completed cycles (median(range)) | 4 (1–6) |
Completion of planned treatment | |
Yes | 22 (45%) |
No | 27 (55%) |
Hospital admission during treatment | |
Yes | 27 (55%) |
No | 22 (45%) |